pyridoxal phosphate has been researched along with Injury, Myocardial Reperfusion in 15 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydrogen sulfide (H( 2)S) is a biological mediator produced by enzyme-regulated pathways from L-cysteine, which is a substrate for cystathionine-gamma-lyase (CSE)." | 1.36 | L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. ( Baxter, GF; Elsey, DJ; Fowkes, RC, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pham, V | 1 |
| Zhang, W | 1 |
| Chen, V | 1 |
| Whitney, T | 1 |
| Yao, J | 1 |
| Froese, D | 1 |
| Friesen, AD | 2 |
| Diakur, JM | 1 |
| Haque, W | 1 |
| García-Villalón, ÁL | 1 |
| Granado, M | 1 |
| Monge, L | 1 |
| Fernández, N | 1 |
| Carreño-Tarragona, G | 1 |
| Amor, S | 1 |
| Oh, J | 1 |
| Hong, N | 1 |
| Kang, SM | 1 |
| Tribble, CG | 1 |
| Millart, H | 1 |
| Alouane, L | 1 |
| Oszust, F | 1 |
| Chevallier, S | 1 |
| Robinet, A | 1 |
| Elsey, DJ | 1 |
| Fowkes, RC | 1 |
| Baxter, GF | 1 |
| Wei, L | 1 |
| Wu, RB | 1 |
| Yang, CM | 1 |
| Zheng, SY | 1 |
| Yu, XY | 1 |
| Hemmingsson, A | 1 |
| Kandzari, DE | 2 |
| Labinaz, M | 1 |
| Cantor, WJ | 1 |
| Madan, M | 1 |
| Gallup, DS | 1 |
| Hasselblad, V | 2 |
| Joseph, D | 1 |
| Allen, A | 1 |
| Green, C | 1 |
| Hidinger, KG | 1 |
| Krucoff, MW | 1 |
| Christenson, RH | 1 |
| Harrington, RA | 3 |
| Tcheng, JE | 1 |
| Kim, TH | 2 |
| Yang, DH | 2 |
| Choi, JW | 2 |
| Kim, ST | 2 |
| Yoon, JH | 2 |
| Shin, JH | 2 |
| Seo, JB | 2 |
| Gong, GY | 1 |
| Lim, TH | 2 |
| Dery, JP | 1 |
| Armstrong, PW | 1 |
| Douglas, DA | 1 |
| Zettler, ME | 1 |
| Hidinger, GK | 1 |
| Alexander, JH | 1 |
| Emery, RW | 1 |
| Carrier, M | 1 |
| Ellis, SJ | 1 |
| Mehta, RH | 1 |
| Menasche, P | 1 |
| Khalil, A | 1 |
| Cote, R | 1 |
| Bennett-Guerrero, E | 1 |
| Mack, MJ | 1 |
| Schuler, G | 1 |
| Tardif, JC | 1 |
| Karlsson, JO | 1 |
| Brurok, H | 1 |
| Eriksen, M | 1 |
| Towart, R | 1 |
| Toft, KG | 1 |
| Moen, O | 1 |
| Engebretsen, B | 1 |
| Jynge, P | 1 |
| Refsum, H | 1 |
| Saeed, M | 1 |
| Wendland, MF | 1 |
| Takehara, Y | 1 |
| Higgins, CB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery[NCT00402506] | Phase 3 | 3,000 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| A Local Feasibility Study on Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Patients Operated Upon Colon Cancer Stage Dukes' C[NCT00671996] | Phase 2 | 14 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pyridoxal phosphate and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury.
Topics: Animals; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Pyr | 2005 |
3 trials available for pyridoxal phosphate and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Industry-sponsored negative trials and the potential pitfalls of post hoc analysis.
Topics: Aged; Confidence Intervals; Coronary Angiography; Coronary Artery Bypass; Coronary Restenosis; Coron | 2008 |
Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Coronary Angiography; Coronary Disease; Do | 2003 |
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
Topics: Aged; Calcium Channel Blockers; Cardiopulmonary Bypass; Coronary Artery Bypass; Double-Blind Method; | 2008 |
11 other studies available for pyridoxal phosphate and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents.
Topics: Animals; Cardiovascular Agents; Coronary Stenosis; Drug Stability; Fatty Acids; Glucose; Glycolysis; | 2003 |
Purinergic component in the coronary vasodilatation to acetylcholine after ischemia-reperfusion in perfused rat hearts.
Topics: Acetylcholine; Animals; Coronary Circulation; Enzyme Inhibitors; Heart; Male; Myocardial Reperfusion | 2014 |
Clopidogrel treatment and the MEND-CABG II trial.
Topics: Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; P | 2008 |
Involvement of P2Y receptors in pyridoxal-5'-phosphate-induced cardiac preconditioning.
Topics: Animals; Creatine Kinase; Disease Models, Animal; Ischemic Preconditioning, Myocardial; Male; Myocar | 2009 |
L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury.
Topics: Alkynes; Analysis of Variance; Animals; Cysteine; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
Cardioprotective effect of a hemoglobin-based oxygen carrier on cold ischemia/reperfusion injury.
Topics: Animals; Blood Substitutes; Cold Ischemia; Down-Regulation; Glucose; Hemoglobins; Interleukin-6; Man | 2011 |
[MnDPDP--contrast medium with protective effect in acute myocardial infarction].
Topics: Animals; Cardiotonic Agents; Contrast Media; Edetic Acid; Mice; Mice, Transgenic; Myocardial Infarct | 2002 |
Manganese dipyridoxyl diphosphate (MnDPDP)-enhanced magnetic resonance imaging of acute reperfused myocardial injury in a cat model: part I: comparison with pathologic examination.
Topics: Acute Disease; Animals; Cats; Contrast Media; Disease Models, Animal; Edetic Acid; Magnetic Resonanc | 2005 |
Manganese dipyridoxyl diphosphate (MnDPDP)-enhanced magnetic resonance imaging of acute reperfused myocardial injury in a cat model: part II: comparison with cine magnetic resonance imaging.
Topics: Acute Disease; Animals; Cats; Contrast Media; Disease Models, Animal; Edetic Acid; Magnetic Resonanc | 2005 |
Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Contrast Media; Coronary Circulation; Disease Models, A | 2001 |
Reversible and irreversible injury in the reperfused myocardium: differentiation with contrast material-enhanced MR imaging.
Topics: Animals; Contrast Media; Edetic Acid; Female; Magnetic Resonance Imaging; Male; Muscles; Myocardial | 1990 |